M&A in Healthcare sparked by Covid-19

26

An article recently released in TheMiddleMarket.com titled: Covid-19 vaccines, tests and treatments spur healthcare M&A discussed how the coronavirus pandemic has disrupted entire industries in 2020. 

No industry, however, was disrupted as much as healthcare.  

The article mentions that “in the recent weeks, there has been a slew of new deal announcements and strategic buyers are rapidly snatching up targets focused on developers targeting a wide range of diseases, including the coronavirus, but not limited to it. 

Johnson & Johnson (NYSE: JNJ) agreed to buy Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) for about $6.5 billion to expand in treatments for autoimmune diseases. And Sanofi (NASDAQ: SNY) said it would buy biotech company Principia Biopharma Inc., which develops treatments for multiple sclerosis and a range of autoimmune disorders, for $3.4 billion, as the French drug maker pivots toward innovative therapies to spur growth.”

Here’s another company that is very attractive based on its current revenues, strong balance sheet, low debt, and growing customer base…

Take a look at Glucose Health, Inc. (OTC Pink: GLUC).  Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®. 

Now…more than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).

The company just announced that they produced their largest production run to date of GLUCODOWN®.  

The run was completed in September and sent to their largest national retail partners including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at Amazon.com (NASDAQ: AMZN) to meet growing consumer demand.  

Despite being on the shelves of national pharmacy chains like Walmart (NYSE: WMT), CVS Health (NYSE: CVS) GLUC is still trading below a $30 million valuation.

GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.

See their latest line of drink mix products here; 

https://www.glucodown.com/glucodown-drink-mixes

Glucose Health, Inc. (OTC Pink: GLUC) recently announced unprecedented consumer demand and 2ndquarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4? 

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list. 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated twelve thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here https://emerginggrowth.com/4582-6827465/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.